GH Research (NASDAQ:GHRS) Given Buy Rating at HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 316.23% from the stock’s previous close.

Other research analysts also recently issued reports about the company. JMP Securities restated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th. Canaccord Genuity Group cut their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday.

GH Research Stock Up 1.5 %

NASDAQ:GHRS opened at $9.61 on Wednesday. GH Research has a 52-week low of $5.05 and a 52-week high of $14.99. The stock has a fifty day simple moving average of $7.82 and a 200-day simple moving average of $10.33. The company has a market capitalization of $499.99 million, a PE ratio of -12.16 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last announced its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. As a group, equities analysts anticipate that GH Research will post -0.85 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP increased its position in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,310,563 shares of the company’s stock after acquiring an additional 1,471,946 shares during the quarter. GH Research makes up approximately 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 at the end of the most recent quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).